Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection

J Antimicrob Chemother. 2014 Apr;69(4):1150-1. doi: 10.1093/jac/dkt472. Epub 2013 Nov 19.

Authors

Bo Zhang¹, Marc Fila, May Fakhoury, Véronique Baudouin, Georges Deschênes, Evelyne Jacqz-Aigrain, Wei Zhao

Affiliation

¹ Emergency Department, The Third Hospital of Hebei Medical University, Shijiazhuang, China.

PMID: 24252753
DOI: 10.1093/jac/dkt472

No abstract available

Keywords: dosage optimization; paediatric pharmacokinetics; paediatric pharmacology; therapeutic drug monitoring.

Publication types

Case Reports
Letter

MeSH terms

Antiviral Agents / administration & dosage
Antiviral Agents / pharmacokinetics*
Antiviral Agents / pharmacology
Creatinine / urine
Cytomegalovirus / isolation & purification
Cytomegalovirus Infections / complications*
Cytomegalovirus Infections / drug therapy*
Drug Monitoring
Ganciclovir / administration & dosage
Ganciclovir / analogs & derivatives*
Ganciclovir / pharmacokinetics*
Ganciclovir / pharmacology
Humans
Infant
Nephrotic Syndrome / complications*
Proteinuria
Treatment Outcome
Urine / chemistry
Valganciclovir
Viral Load

Substances

Antiviral Agents
Creatinine
Valganciclovir
Ganciclovir